Aviragen Therapeutics Announces the Appointment of Jonas Niaura as Vice President, Corporate Development and Strategy
June 28 2016 - 9:00AM
Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company
that is developing the next generation of antivirals, today
announced the appointment of Jonas Niaura as Vice President,
Corporate Development and Strategy.
“Jonas brings to Aviragen considerable business
development experience in the field of infectious diseases from
large pharma and several biotech companies,” commented Joseph
Patti, PhD, president and chief executive officer of Aviragen. “As
we approach data readouts from our Phase 2b SPIRITUS trial and our
Phase 2a BTA585 RSV challenge study, we are excited to welcome
Jonas to the Aviragen team to explore our growing number of
business development opportunities.”
Prior to joining Aviragen, Mr. Niaura was Head of
Search and Evaluation for Infection, Neuroscience, and GI at
AstraZeneca. Before joining AstraZeneca, he served as Senior
Director of Business Development at AMAG Pharmaceuticals. Earlier,
he was Director of Business Development at Achillion
Pharmaceuticals. Mr. Niaura holds an M.B.A. from the Yale School of
Management and a B.S. in Chemical Engineering and Chemistry from
the University of Illinois at Champaign-Urbana.
Mr. Niaura commented, "As a leader in the
development of antiviral therapies with a robust portfolio of
clinical stage programs, Aviragen is an exciting growth story and I
look forward to developing and executing value-creating business
opportunities."
About Aviragen Therapeutics, Inc.Aviragen
Therapeutics is focused on the discovery and development of the
next generation of direct-acting antivirals to treat infections
that have limited therapeutic options and affect a significant
number of patients globally. The Company has three product
candidates in active clinical development: These include
vapendavir, an oral treatment for human rhinovirus (HRV) upper
respiratory infections in moderate-to-severe asthmatics currently
being evaluated in the Phase 2b SPIRITUS trial; BTA585, an oral
fusion protein inhibitor that has received Fast Track designation
by the U.S. FDA, in Phase 2 development for the treatment and
prevention of respiratory syncytial virus (RSV) infections; and
BTA074, a topical antiviral treatment in Phase 2 development for
condyloma caused by human papillomavirus types 6 & 11. For
additional information about the Company, please visit
www.aviragentherapeutics.com.
Contacts:
Mark Colonnese
Executive Vice President and Chief Financial Officer
Aviragen Therapeutics, Inc.
(678) 221-3381
mcolonnese@aviragentherapeutics.com
Beth DelGiacco
Stern Investor Relations, Inc.
(212) 362-1200
beth@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2023 to Apr 2024